Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Duncan J. Topliss, Stefan D. Anker et al.|Diabetes Care|2022Cited by 207
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 DiabetesSharon L. Mulvagh, Mariano I. Chahin, J Deanfield et al.|JAMA Cardiology|2026Cited by 4